- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07755761
Innovative Tube Trabeculectomy for Advanced and Refractory Glaucoma: A Randomized Controlled Trial (ITT-RCT)
A Prospective, Randomized, Controlled, Single-Center Clinical Trial to Evaluate the Efficacy and Safety of Innovative Tube Trabeculectomy Compared to Conventional Trabeculectomy in Patients With Advanced and Refractory Glaucoma
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ahmed M Saeed, MD
- Numéro de téléphone: 01227468426
- E-mail: ahmed.abdelhamid@fmed.bu.edu.eg
Lieux d'étude
-
-
-
Banhā, Egypte, 13518
- Recrutement
- Ophthalmology department, Faculty of Medicine, Benha University
-
Contact:
- Mohamed G AlAshhab, MD
- Numéro de téléphone: 0133227518
- E-mail: info@fmed.bu.edu.eg
-
Sous-enquêteur:
- Tarek Abulnasr, MD
-
Chercheur principal:
- Ahmed M Saeed, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- • Diagnosis of advanced or refractory primary open-angle glaucoma (POAG) or secondary open-angle glaucoma (excluding neovascular glaucoma).
- Intraocular pressure (IOP) > 21 mmHg despite maximal tolerated medical therapy or previous failed glaucoma surgery.
- Best corrected visual acuity (BCVA) of 20/400 or better.
- Capable of providing informed consent
Exclusion Criteria:
- Previous incisional glaucoma surgery in the study eye (except for prior failed trabeculectomy in the refractory group).
- Neovascular glaucoma or other forms of secondary glaucoma that may significantly impact wound healing (e.g., uveitic glaucoma).
- Significant ocular comorbidities that may confound outcome assessment (e.g., severe corneal disease, retinal detachment).
- Pregnancy or lactation.
- Participation in another clinical trial within 30 days prior to enrollment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1: Innovative Tube Trabeculectomy (ITT)
Patients will undergo the innovative tube trabeculectomy procedure.
This includes a 3-week preoperative regimen (discontinuation of preserved medications and prostaglandin analogs, initiation of fluorometholone), a 1-week preoperative subconjunctival injection (Mitomycin C 0.04%, Avastin 1.25 mg, Dexamethasone 8 mg), and the surgical technique involving a deep extended scleral tunnel, intraoperative Mitomycin C application, X-shaped non-absorbable suture, and nasolacrimal tube implantation.
|
Patients will undergo the innovative tube trabeculectomy procedure.
This includes a 3-week preoperative regimen (discontinuation of preserved medications and prostaglandin analogs, initiation of fluorometholone), a 1-week preoperative subconjunctival injection (Mitomycin C 0.04%, Avastin 1.25 mg, Dexamethasone 8 mg), and the surgical technique involving a deep extended scleral tunnel, intraoperative Mitomycin C application, X-shaped non-absorbable suture, and nasolacrimal tube implantation.
|
|
Comparateur actif: Arm 2: Conventional Trabeculectomy
Patients will undergo standard conventional trabeculectomy with intraoperative Mitomycin C application (concentration and duration as per standard practice at the study site).
|
Patients will undergo standard conventional trabeculectomy with intraoperative Mitomycin C application (concentration and duration as per standard practice at the study site
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
• Measure: Surgical success, defined as Intraocular Pressure (IOP) ≤ 15 mmHg and ≥ 20% reduction from baseline without glaucoma medications.
Délai: 12 months post-surgery
|
The proportion of eyes achieving the defined surgical success criteria
|
12 months post-surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
• Measure: Mean Intraocular Pressure (IOP)
Délai: • Time Frame: 3, 6, and 12 months post-surgery
|
Average IOP measured at each follow-up visit.
|
• Time Frame: 3, 6, and 12 months post-surgery
|
|
• Measure: Number of Glaucoma Medications
Délai: 3, 6, and 12 months post-surgery
|
Average number of glaucoma medications required to maintain target IOP.
|
3, 6, and 12 months post-surgery
|
|
• Measure: Incidence of Surgical Complications
Délai: From surgery to 12 months post-surgery
|
Rate and type of complications, including hypotony, bleb leakage, infection, tube exposure/migration, and choroidal detachment.
|
From surgery to 12 months post-surgery
|
|
• Measure: Bleb Morphology and Function
Délai: 6 and 12 months post-surgery
|
Assessment using Ultrasound Biomicroscopy (UBM) and Anterior Segment Optical Coherence Tomography (AS-OCT).
|
6 and 12 months post-surgery
|
|
• Measure: Best Corrected Visual Acuity (BCVA)
Délai: 3, 6, and 12 months post-surgery
|
Change in BCVA from baseline
|
3, 6, and 12 months post-surgery
|
|
• Measure: Visual Field Mean Deviation (MD)
Délai: 6 and 12 months post-surgery
|
Change in visual field mean deviation from baseline
|
6 and 12 months post-surgery
|
|
• Measure: Quality of Life (QoL)
Délai: 6 and 12 months post-surgery
|
Patient-reported outcomes using the NEI VFQ-25 questionnaire.
|
6 and 12 months post-surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Tarek Abulnasr, MD, Benha University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Innovative Tube Trabeculectomy
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
What IPD will be shared? De-identified individual participant data that underlie the results reported in the final study, including demographic characteristics and ocular surface/meibomian gland assessment parameters.
Supporting Documents: The study protocol and statistical analysis plan will be made available.
When will data be available? Data will be available beginning 6 months and ending 36 months following the official publication of the study results.
With whom? Data will be shared with qualified researchers who provide a methodologically sound proposal that is approved by the study investigators.
For what types of analyses? To achieve the specific aims outlined in the approved research proposal.
By what mechanism will data be made available? Interested researchers should contact the corresponding author via email to submit a formal request and a data use agreement.
Délai de partage IPD
Critères d'accès au partage IPD
Data will be shared with qualified researchers who provide a methodologically sound proposal that is approved by the study investigators.
Interested researchers should contact the corresponding author via email to submit a formal request and a data use agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .